–Completed sale to Sentynl Therapeutics of BridgeBio’s NULIBRY™ (Fosdenopterin) for Injection –Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn –Released […]
Other News
FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction
Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction WILMINGTON, Del.–(BUSINESS WIRE)–High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a statistically significant and clinically meaningful reduction in the primary composite endpoint of cardiovascular (CV) death or […]
Clarius Receives CE Mark Certification for Seven New Ultra-Portable Wireless Ultrasound Scanners for Apple and Android Devices
Miniaturized to the size of an iPhone, the third-generation ultrasound scanners make high-definition ultrasound affordable for more doctors across specialties in Europe VANCOUVER, British Columbia–(BUSINESS WIRE)–Clarius Mobile Health is first to introduce a third-generation product line of high-performance wireless ultrasound scanners in the European Union and United Kingdom. Now 30% lighter […]
Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results
Conference Call Scheduled for Today, May 4, 2022, at 8:00 a.m. CT (9:00 a.m. ET) Revenues of $56.2 million decreased 4.9% sequentially compared to second quarter this year and decreased 11.1% compared to third quarter last year Fiscal year 22 revenue guidance narrowed to $235 million to $240 million Announced […]
AtriCure Reports First Quarter 2022 Financial Results
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results. “Our team delivered exceptional first quarter performance, with broad-based growth across all key products,” said Michael Carrel, […]
DiA Imaging Analysis Named one of FAST COMPANY’S 2022 World Changing Ideas in Health Category
FAST COMPANY honored DiA’s innovative LVivo Toolbox software leveraging AI to automate the way clinicians analyze ultrasound images BEER SHEVA, Israel, May 4, 2022 /PRNewswire/ — DiA Imaging Analysis – a global leading provider of ultrasound AI-based software solutions – has been recognized in the health category for Fast Company‘s World Changing Ideas Awards. DiA’s AI-powered cardiac and abdominal ultrasound analysis software allows clinicians with […]
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook
Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million. Core non-COVID-19 product sales were an estimated $7.6 million, and on a constant currency basis were comparable to core product sales a year ago. Product gross margins were 80%. MONMOUTH JUNCTION, N.J., May 3, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the […]
CathVision Announces FDA Clearance of ECGenius™ High-Fidelity, Low-Noise EP Recording Technology
ECGenius Sets a New Standard for ECG Signal Detection, Interpretation and Therapy Support COPENHAGEN, Denmark , May 4, 2022 /PRNewswire/ — CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the FDA 510(k) clearance of the ECGenius EP Recording System. ECGenius, the […]
Ionis reports first quarter financial results and recent business achievements
On track to achieve 2022 financial guidance Webcast today, May 4, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif., May 4, 2022 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported financial results for the first quarter of 2022 and recent business achievements. “We are off to a strong start this year highlighted by progress in our […]
Leveraging the science of hibernation to improve human heart health
EMERYVILLE, Calif., May 4, 2022 /PRNewswire/ — Discovering new ways to treat heart and lung diseases by tapping into the natural disease resistance of hibernating animals is the focus of a new partnership between Monash University and Fauna Bio, a U.S. biotechnology company. Hibernation requires mechanisms of self-healing and tissue repair to endure […]